NO DOUBT WE ARE HAVING AN ORAL SESSION!!!!
Details for the oral presentation are as follows:
Title:ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Multiple Solid and Hematological Cancer Indications
Oral Session:Targeted Gene and Cell Therapy Session I
Presenting Author: Shon Green, Ph.D.
Date & Time: May 10, 2024at5:00 PM EST
AboutAdicet Bio, Inc.
Adicet Bio, Inc.is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website athttps://www.adicetbio.com.
Details for the oral presentation are as follows:
Title:ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Multiple Solid and Hematological Cancer Indications
Oral Session:Targeted Gene and Cell Therapy Session I
Presenting Author: Shon Green, Ph.D.
Date & Time: May 10, 2024at5:00 PM EST
AboutAdicet Bio, Inc.
Adicet Bio, Inc.is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website athttps://www.adicetbio.com.
